Tyler Lipschultz was appointed President, Global Biologics following the merger. Mr. Lipschultz previously served as Senior Vice President, Orthobiologics and Business Development at SeaSpine since 2018 and served as Vice President, Orthobiologics and Business Development at SeaSpine from 2015 to 2018. Before joining SeaSpine, from 2008 to 2015, Mr. Lipschultz held positions of increasing responsibility at NuVasive, Inc., a publicly traded medical device company, most recently serving as its Executive Vice President, Global Operations and, prior to that, Executive Vice President, Biologics. Prior to joining NuVasive, he was a Director at ProtoStar, a medical device incubator that formed Annulex, CVRx, and VERTx, which Mr. Lipschultz cofounded. In 2002, VERTx merged with Spine Wave, where he subsequently served in a variety of roles, including Executive Vice President and General Manager of the mechanical business. Prior to ProtoStar, Mr. Lipschultz held the position of Equity Research Analyst at Piper Jaffray and served in various marketing/product management roles at Stryker, Smith & Nephew, and DePuy. He received a B.A. in Economics and Business Administration from Kalamazoo College and an M.B.A. from the executive program at Krannert School of Management at Purdue University.